BrainsWay Announces Launch of Noninvasive Treatment for Smoking Addiction to U.S. Providers
29 Aprile 2021 - 3:03PM
BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the
“Company”), a global leader in advanced noninvasive treatment of
brain disorders, today announced the distribution of its first 10
Deep Transcranial Magnetic Stimulation (Deep TMS) devices for
smoking addiction to practices across the United States. The
recently FDA-cleared aid for short-term smoking cessation offers a
noninvasive treatment that administers electromagnetic pulses using
BrainsWay’s patented H4-coil through a cushioned helmet,
stimulating neurons in brain structures associated with addiction.
“Tobacco smoking is one of the leading causes of
preventable disease and death throughout the world,” said
Christopher von Jako, Ph.D., President and Chief Executive Officer
of BrainsWay. “We have seen lives drastically changed after
undergoing Deep TMS treatment and are eager to bring this same hope
to those who desire to quit smoking. Research shows that there is
often comorbidity between tobacco use and mental disorders, and the
COVID-19 pandemic has exacerbated both. Many patients have given up
trying to quit, but now, with a noninvasive option like Deep TMS,
we are hopeful they are able to take that step.”
Deep TMS is the first FDA-cleared noninvasive
treatment in the addiction space for any TMS device, and currently
serves as the only TMS platform technology with clinical outcome
data for multiple brain disorders. In 2019, a double-blind,
sham-controlled, multicenter randomized controlled trial of 262
patients found Deep TMS to be an effective treatment, significantly
improving the continuous quit rate, as well as reducing craving and
the average number of cigarettes smoked per week. Participants in
the study were highly addicted to smoking with a history of smoking
an average of over 26 years and multiple failed attempts to
quit.
Deep TMS treatment for smoking addiction is
currently available at the following clinics:
- Advanced Mental Health Care in Palm
Beach, FL
- Brooklyn Minds in New York, NY
- Delray Center for Healing in Delray
Beach, FL
- Greenbrook TMS NeuroHealth in
Richmond Heights, MO
- Houston TMS Therapeutics in
Bellaire, TX
- Kadima Neuropsychiatry
Institute in La Jolla, CA
- Medical University of South
Carolina (MUSC) in Charleston, SC
- Novus TMS in Tuscaloosa, AL
- PsyCare Inc. in Charleston, WV
- TMS NW in Vancouver, WA
For more information on Deep TMS treatment for
smoking addiction, visit www.brainsway.com.
About BrainsWayBrainsWay is a
global leader in advanced noninvasive neurostimulation treatments
for mental health disorders. The Company is boldly advancing
neuroscience with its proprietary Deep Transcranial Magnetic
Stimulation (Deep TMS) platform technology to improve health and
transform lives. BrainsWay is the first and only TMS company to
obtain three FDA-cleared indications backed by pivotal studies
demonstrating clinically proven efficacy. Current indications
include major depressive disorder, obsessive-compulsive disorder,
and smoking addiction. The Company is dedicated to leading through
superior science and building on its unparalleled body of clinical
evidence. Additional clinical trials of Deep TMS in various
psychiatric, neurological, and addiction disorders are underway.
Founded in 2003, with offices in Cresskill, NJ and Jerusalem,
Israel, BrainsWay is committed to increasing global awareness and
broad access to Deep TMS. For the latest news and information about
BrainsWay, please visit www.brainsway.com.
Forward Looking Statements
This press release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements may be preceded by the words
“intends,” “may,” “will,” “plans,” “expects,” “anticipates,”
“projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,”
“potential” or similar words, and include, but are not limited to,
statements about the expected proceeds, use of proceeds and closing
of the underwritten offering. These forward-looking statements and
their implications are based on the current expectations of the
management of the Company only and are subject to a number of
factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
The following factors, among others, could cause actual results to
differ materially from those described in the forward-looking
statements: inadequacy of financial resources to meet future
capital requirements; changes in technology and market
requirements; delays or obstacles in launching and/or successfully
completing planned studies and clinical trials; failure to obtain
approvals by regulatory agencies on the Company’s anticipated
timeframe, or at all; inability to retain or attract key employees
whose knowledge is essential to the development of Deep TMS
products; unforeseen difficulties with Deep TMS products and
processes, and/or inability to develop necessary enhancements;
unexpected costs related to Deep TMS products; failure to obtain
and maintain adequate protection of the Company’s intellectual
property, including intellectual property licensed to the Company;
the potential for product liability; changes in legislation and
applicable rules and regulations; unfavorable market perception and
acceptance of Deep TMS technology; inadequate or delays in
reimbursement from third-party payers, including insurance
companies and Medicare; inability to commercialize Deep TMS,
including internationally, by the Company or through third-party
distributors; product development by competitors; inability to
timely develop and introduce new technologies, products and
applications, and the effect of the global COVID-19 health pandemic
on our business and continued uncertainty and market impact
relating thereto.
Any forward-looking statement in this press
release speaks only as of the date of this press release. The
Company undertakes no obligation to publicly update or review any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by any
applicable securities laws. More detailed information about the
risks and uncertainties affecting the Company is contained under
the heading “Risk Factors” in the Company’s filings with the U.S.
Securities and Exchange Commission, including the Company's Annual
Report on Form 20-F. Investors and security holders are urged to
read these documents free of charge on the SEC’s web site at
http://www.sec.gov.
Contact: BrainsWay:Hadar LevySVP and General
ManagerHadarL@brainsway.com
Media Contact:Will Johnson(201)
465-8019Brainsway@antennagroup.com
Grafico Azioni Brainsway (NASDAQ:BWAY)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni Brainsway (NASDAQ:BWAY)
Storico
Da Ott 2023 a Ott 2024